Browsing publications by Dr Mark Verrill

Newcastle AuthorsTitleYear
Dr David Jamieson
Dr Nicola Cresti
Julieann Sludden
Melanie Griffin
Nahed Hawsawi
et al.
Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy2011
Dr Christopher Plummer
Dr Mark Verrill
Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials2010
Julieann Sludden
Melanie Griffin
Mike Cole
Dr Mark Verrill
Dr David Jamieson
et al.
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide2010
Dr Mark Verrill
Capecitabine and vinorelbine in metastatic breast cancer2009
Dr David Jamieson
Dr Nicola Cresti
Dr Mark Verrill
Professor Alan Boddy
Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma2009
Dr Christopher Plummer
Dr Mark Verrill
Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk2009
Dr Fathi Azribi
Dr Petra Dildey
Dr John Wilsdon
Dr Mark Verrill
Imatinib in gastrointestinal stromal tumour (GIST): Northern cancer network experience2009
Professor Ruth Plummer
Professor Alan Boddy
Melanie Griffin
Dr Mark Verrill
A phase I and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies2008
Dr Mark Verrill
Dr Christopher Plummer
DEVELOPMENT AND IMPLEMENTATION OF NEW UK NATIONAL CANCER RESEARCH INSTITUTE (NCRI) GUIDELINES FOR PREVENTING AND MANAGING CARDIAC EVENTS WITH TRASTUZUMAB2008
Dr Elizabeth McIntyre
Dr Mark Verrill
Dr Richard Quinton
Professor Simon Pearce
Lesson of the week: Unrecognised severe hypovitaminosis D2008
12345